These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 34688376)

  • 1. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
    Keeton R; Richardson SI; Moyo-Gwete T; Hermanus T; Tincho MB; Benede N; Manamela NP; Baguma R; Makhado Z; Ngomti A; Motlou T; Mennen M; Chinhoyi L; Skelem S; Maboreke H; Doolabh D; Iranzadeh A; Otter AD; Brooks T; Noursadeghi M; Moon JC; Grifoni A; Weiskopf D; Sette A; Blackburn J; Hsiao NY; Williamson C; Riou C; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Moore PL; Burgers WA
    Cell Host Microbe; 2021 Nov; 29(11):1611-1619.e5. PubMed ID: 34688376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
    Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Lawpoolsri S; Nanthapisal S; Jongkaewwattana A; Duangdee C; Kamolratanakul S; Luvira V; Thanthamnu N; Chantratita N; Thitithanyanont A; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2024 Jul; 42(19):3999-4010. PubMed ID: 38744598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
    Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
    PLoS Pathog; 2023 Nov; 19(11):e1011772. PubMed ID: 37943890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
    Sadoff J; Le Gars M; Shukarev G; Heerwegh D; Truyers C; de Groot AM; Stoop J; Tete S; Van Damme W; Leroux-Roels I; Berghmans PJ; Kimmel M; Van Damme P; de Hoon J; Smith W; Stephenson KE; De Rosa SC; Cohen KW; McElrath MJ; Cormier E; Scheper G; Barouch DH; Hendriks J; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H
    N Engl J Med; 2021 May; 384(19):1824-1835. PubMed ID: 33440088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.
    Yu J; Tostanoski LH; Mercado NB; McMahan K; Liu J; Jacob-Dolan C; Chandrashekar A; Atyeo C; Martinez DR; Anioke T; Bondzie EA; Chang A; Gardner S; Giffin VM; Hope DL; Nampanya F; Nkolola J; Patel S; Sanborn O; Sellers D; Wan H; Hayes T; Bauer K; Pessaint L; Valentin D; Flinchbaugh Z; Brown R; Cook A; Bueno-Wilkerson D; Teow E; Andersen H; Lewis MG; Martinot AJ; Baric RS; Alter G; Wegmann F; Zahn R; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7872):423-427. PubMed ID: 34161961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
    Cárdenas V; Le Gars M; Truyers C; Ruiz-Guiñazú J; Struyf F; Colfer A; Bonten M; Borobia A; Reisinger EC; Kamerling IMC; Douoguih M; Sadoff J
    Vaccine; 2024 Jun; 42(16):3536-3546. PubMed ID: 38705804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
    Roozendaal R; Solforosi L; Stieh DJ; Serroyen J; Straetemans R; Dari A; Boulton M; Wegmann F; Rosendahl Huber SK; van der Lubbe JEM; Hendriks J; Le Gars M; Dekking L; Czapska-Casey DN; Guimera N; Janssen S; Tete S; Chandrashekar A; Mercado NB; Yu J; Koudstaal W; Perez-Ruixo JJ; Sadoff J; Barouch DH; Schuitemaker H; Zahn R
    Nat Commun; 2021 Oct; 12(1):5877. PubMed ID: 34620860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
    Kitchin D; Richardson SI; van der Mescht MA; Motlou T; Mzindle N; Moyo-Gwete T; Makhado Z; Ayres F; Manamela NP; Spencer H; Lambson B; Oosthuysen B; Kaldine H; du Pisanie M; Mennen M; Skelem S; Williams N; Ntusi NAB; Burgers WA; Gray GG; Bekker LG; Boswell MT; Rossouw TM; Ueckermann V; Moore PL
    Cell Rep Med; 2022 Mar; 3(3):100535. PubMed ID: 35474744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
    Richardson SI; Manamela NP; Motsoeneng BM; Kaldine H; Ayres F; Makhado Z; Mennen M; Skelem S; Williams N; Sullivan NJ; Misasi J; Gray GG; Bekker LG; Ueckermann V; Rossouw TM; Boswell MT; Ntusi NAB; Burgers WA; Moore PL
    Cell Rep Med; 2022 Feb; 3(2):100510. PubMed ID: 35233544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
    Stephenson KE; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Truyers C; Atyeo C; Loos C; Chandrashekar A; McMahan K; Tostanoski LH; Yu J; Gebre MS; Jacob-Dolan C; Li Z; Patel S; Peter L; Liu J; Borducchi EN; Nkolola JP; Souza M; Tan CS; Zash R; Julg B; Nathavitharana RR; Shapiro RL; Azim AA; Alonso CD; Jaegle K; Ansel JL; Kanjilal DG; Guiney CJ; Bradshaw C; Tyler A; Makoni T; Yanosick KE; Seaman MS; Lauffenburger DA; Alter G; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H; Barouch DH
    JAMA; 2021 Apr; 325(15):1535-1544. PubMed ID: 33704352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
    Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
    Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
    Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
    Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
    Solforosi L; Kuipers H; Jongeneelen M; Rosendahl Huber SK; van der Lubbe JEM; Dekking L; Czapska-Casey DN; Izquierdo Gil A; Baert MRM; Drijver J; Vaneman J; van Huizen E; Choi Y; Vreugdenhil J; Kroos S; de Wilde AH; Kourkouta E; Custers J; van der Vlugt R; Veldman D; Huizingh J; Kaszas K; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; Barouch DH; Böszörményi KP; Stammes MA; Kondova I; Verschoor EJ; Verstrepen BE; Koopman G; Mooij P; Bogers WMJM; van Heerden M; Muchene L; Tolboom JTBM; Roozendaal R; Brandenburg B; Schuitemaker H; Wegmann F; Zahn RC
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33909009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
    He X; Chandrashekar A; Zahn R; Wegmann F; Yu J; Mercado NB; McMahan K; Martinot AJ; Piedra-Mora C; Beecy S; Ducat S; Chamanza R; Huber SR; van Heerden M; van der Fits L; Borducchi EN; Lifton M; Liu J; Nampanya F; Patel S; Peter L; Tostanoski LH; Pessaint L; Van Ry A; Finneyfrock B; Velasco J; Teow E; Brown R; Cook A; Andersen H; Lewis MG; Schuitemaker H; Barouch DH
    Cell; 2021 Jun; 184(13):3467-3473.e11. PubMed ID: 34133941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
    Darling TL; Ying B; Whitener B; VanBlargan LA; Bricker TL; Liang CY; Joshi A; Bamunuarachchi G; Seehra K; Schmitz AJ; Halfmann PJ; Kawaoka Y; Elbashir SM; Edwards DK; Thackray LB; Diamond MS; Boon ACM
    Med; 2022 May; 3(5):309-324.e6. PubMed ID: 35584653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Le Gars M; Sadoff J; Cárdenas V; Heerwegh D; Tesfaye F; Roey GV; Spicer C; Matias SS; Crayne O; Kamphuis T; Struyf F; Schuitemaker H; Douoguih M
    Vaccine; 2024 Jul; 42(19):3938-3952. PubMed ID: 38918103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.